Chronically altered NMDAR signaling in epilepsy mediates comorbid depression

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Biology

Background:

• Depression frequently co-occurs with epilepsy, but its molecular underpinnings are not fully understood.
• The N-methyl-D-aspartate receptor (NMDAR) pathway is implicated due to long-term signaling changes after excitotoxic damage.

Purpose of the Study:

• To investigate molecular pathways in fluoxetine-resistant epilepsy-associated depression (EAD).
• To evaluate the combined efficacy of fluoxetine and 7-nitroindazole (NI) in an EAD animal model.
• To identify molecular targets for treating EAD.

Main Methods:

• Utilized an animal model of fluoxetine-resistant EAD.
• Assessed depressive symptoms using the forced swim test.
• Measured expression and phosphorylation of ERK/CREB/ELK1/BDNF/cFOS pathway markers and oxidative stress markers.

Main Results:

• The combination of fluoxetine and NI showed a synergistic antidepressant effect, unlike either treatment alone.
• Depressive symptoms in epileptic rats correlated with decreased ERK2 expression and ELK1/CREB phosphorylation.
• Treatment with fluoxetine and NI reversed these molecular changes, increasing BDNF and cFOS expression.
• NI appeared to enhance fluoxetine's effect by reducing oxidative stress.

Conclusions:

• Alterations in NMDAR signaling are key contributors to EAD development.
• The synergistic combination of fluoxetine and NI offers a promising therapeutic strategy for EAD.
• Targeting NMDAR signaling pathways may be effective for conditions involving excitotoxic neuronal damage.